» Articles » PMID: 18793669

Regulation of Chemokine Activity by Posttranslational Modification

Overview
Journal Pharmacol Ther
Specialty Pharmacology
Date 2008 Sep 17
PMID 18793669
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokines regulate leukocyte migration during physiological and pathological conditions. They exert their biological activity through interaction with 7-transmembrane spanning G protein-coupled receptors (GPCR) and are presented on glycosaminoglycans (GAG) linked to endothelial cell layers. Specific chemokines and chemokine receptors affect angiogenesis or are targets for viral mimicry, e.g. by human immunodeficiency virus (HIV). Several enzymes, in particular proteases, have been described to process chemokines at specific sites generating chemokine isoforms that were also identified from natural sources. For some chemokines, e.g. CXCL8 and CCL3L1, posttranslational modification results in enhanced biological activity. For CXCL7 and CCL14 truncation is even mandatory for receptor signaling and chemotactic properties. The activity of many other chemokines is down-regulated by processing and receptor antagonists are generated, e.g. for truncated CCL8 and CCL11. Moreover, some processed chemokines such as CCL5(3-68) show enhanced affinity for one receptor (CCR5) and reduced interaction with other receptors (CCR1 and CCR3) resulting in differential changes in leukocyte response. These posttranslational mechanisms, in addition to gene duplication, transcriptional and translational regulation of chemokine ligand and receptor expression, GAG binding properties, expression of "silent" receptors and synergistic interaction between chemokines, modulate chemokine activity in a complex manner. This report reviews current understanding on the regulation of the chemokine network through posttranslational modification and its consequences for leukocyte migration, angiogenesis and protection against viral infection.

Citing Articles

The chemokine receptor CCR8 is not a high-affinity receptor for the human chemokine CCL18.

Hussain K, Lim H, Devkota S, Kemp-Harper B, Lane J, Canals M PLoS One. 2024; 19(9):e0305312.

PMID: 39259753 PMC: 11389940. DOI: 10.1371/journal.pone.0305312.


The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy.

Giacobbi N, Mullapudi S, Nabors H, Pyeon D Viruses. 2024; 16(2).

PMID: 38400076 PMC: 10892169. DOI: 10.3390/v16020302.


CCL5's Role in Periodontal Disease: A Narrative Review.

Barczak K, Drozdzik A, Bosiacki M, Lagocka R, Cenariu D, Uriciuc W Int J Mol Sci. 2023; 24(24).

PMID: 38139161 PMC: 10744061. DOI: 10.3390/ijms242417332.


Neutrophil-to-lymphocyte ratio as a promising non-invasive biomarker for symptom assessment and diagnosis of interstitial cystitis/bladder pain syndrome.

Ke H, Zhu L, Wang Q, Xu K BMC Urol. 2023; 23(1):180.

PMID: 37940904 PMC: 10633971. DOI: 10.1186/s12894-023-01353-z.


Bioinformatic Analysis of the CXCR2 Ligands in Cancer Processes.

Korbecki J, Bosiacki M, Chlubek D, Baranowska-Bosiacka I Int J Mol Sci. 2023; 24(17).

PMID: 37686093 PMC: 10487711. DOI: 10.3390/ijms241713287.